Inhibikase Therapeutics

IKTNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$322.328 M

$2.31 +5.00%

Close of 22 Sept 2026

Revenue

$0.00

#3637 by revenue

Earnings

-$48.3M

Loss-making

Shares outstanding

139,535,900

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#81X4 PharmaceuticalsXFOR$340.1M
#82Lexeo TherapeuticsLXEO$333.9M
#83Inhibikase TherapeuticsIKT$322.3M
#84SAB BiotherapeuticsSABS$318.5M
#85Fate TherapeuticsFATE$309.1M

What if Inhibikase Therapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$216,675.20

Per share 93,799× higher

Bitcoin $1.74T

$12,481.77

Per share 5,403× higher

Nvidia $5.52T

$39,529.38

Per share 17,112× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for Inhibikase Therapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.